eHealth

EHTH · NASDAQ

$0.5783+$0.0132 (+2.34%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $0.5651

EHTH analyst rating

HoldConsensus of 3 analysts over the last 12 months. 0% rate it a buy.

Strong buy0
Buy0
Hold3
Underperform0
Sell0

12-month price target · 6 analysts

Average $1.85 (+219.7% upside)

Low: $1.51
Now: $0.5783
High: $2.10

Upgrades and downgrades

The latest rating actions, newest first

EHTH analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
RBC Capital	Aug 25, 2026	Maintains	Sector Perform	$3.00 → $2.00	57%
UBS	Aug 5, 2026	Maintains	Neutral	$2.00 → $1.75	60%
RBC Capital	Mar 11, 2026	Maintains	Sector Perform	$9.00 → $3.00	57%
Craig-Hallum	Feb 26, 2026	Downgrade	Buy → Hold	$2.00	51%
RBC Capital	Nov 25, 2025	Maintains	Sector Perform	$10.00 → $9.00	57%

The case for and against

Updated Nov 7, 2025

Bull case

eHealth Inc. reported a 13.8% year-over-year increase in approved members, reaching a total of 111.8K, driven primarily by a notable 25.7% growth in Medicare Advantage approved members. The company also achieved a revenue increase of 21.7% year-over-year, totaling $113.1 million, surpassing both internal and consensus estimates. This positive financial performance is attributed to effective marketing strategies and enhancements in telephonic and online conversion rates, suggesting a strengthened market position.

Bear case

eHealth Inc is facing a negative outlook primarily due to a projected increase in turnover during the upcoming 2025 Annual Enrollment Period (AEP), which raises concerns about the company's long-term value (LTV) assumptions. Notably, the company has reported a year-over-year decline in Medicare Average Lifetime Value (MA LTV) of 4.7%, now standing at $907, indicating reduced profitability from its primary revenue-generating segment. Despite management's efforts to reduce operating expenses, with technology and content expenses down 3.4% and general and administrative (G&A) expenses decreasing by 7.7% year-over-year, the overall financial health remains overshadowed by potential revenue instability stemming from anticipated customer turnover.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.